Teva's reslizumab delivers clinically and statistically significant reduction in asthma
Teva announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma exacerbations compared to placebo in two pivotal Phase III studies. September 02, 2014